Overexpression of $G_{sa}$ Protein in the Hearts of Transgenic Mice

Christophe Gaudin, Yoshihiro Ishikawa, David C. Wight, Vijak Mahdavi, Bernardo Nadal-Ginard, Thomas E. Wagner, Dorothy E. Vatner, and Charles J. Homcy

*Department of Pharmacology and 1Department of Medicine, College of Physicians and Surgeons of Columbia University, New York 10032; 4Edison Animal Biotechnology Center, Ohio University, Athens, Ohio, 45701; 1Departments of Cardiology, Howard Hughes Medical Institute, Children’s Hospital, and Harvard Medical School, Boston, Massachusetts 02115; New England Regional Primate Research Center, Southborough, Massachusetts 01772; and **Medical Research Division, American Cyanamid Company, Pearl River, New York 10965

Abstract

Alterations in $\beta$-adrenergic receptor-$G_{sa}$-adenyllyl cyclase coupling underlie the reduced catecholamine responsiveness that is a hallmark of human and animal models of heart failure. To study the effect of altered expression of $G_{sa}$, we overexpressed the short isof orm of $G_{sa}$ in the hearts of transgenic mice, using a rat $\alpha$-myosin heavy chain promoter. $G_{sa}$ mRNA levels were increased selectively in the hearts of transgenic mice, with a level 38 times the control. Despite this marked increase in mRNA, Western blotting identified only a 2.8-fold increase in the content of the $G_{sa}$ short isof orm, whereas $G_{sa}$ activity was increased by 88%. The discrepancy between $G_{sa}$ mRNA and $G_{sa}$ protein levels suggests that the membrane content of $G_{sa}$ is posttranscriptionally regulated. The steady-state adenyllyl cyclase catalytic activity was not altered under either basal or stimulated conditions (GTP + isoproterenol, GTPyS, NaF, or forskolin). However, progress curve studies did show a significant decrease in the lag period necessary for GppNHp to stimulate adenyllyl cyclase activity. Furthermore, the relative number of $\beta$-adrenergic receptors binding agonist with high affinity was significantly increased. Our data demonstrate that a relatively small increase in the amount of the coupling protein $G_{sa}$ can modify the rate of catalyst activation and the formation of agonist high affinity receptors. (J. Clin. Invest. 1995. 95:1676–1683.) Key words: $G_{sa}$ protein overexpression $\alpha$-myosin heavy chain ($\alpha$-MHC) promoter cardiac expression transgenic mice stoichiometry

Introduction

The GTP-binding heterotrimeric regulatory protein (G$_v$) couples a variety of cell surface receptors, including the $\beta$-adrenergic receptor to activation of adenyllyl cyclase. It is composed of $\alpha$, $\beta$, and $\gamma$ subunits and is a member of a large multigene family whose protein products play pivotal roles in mediating signal transduction across the cell membrane (1). Alterations in $\beta$-adrenergic receptor-$G_{sa}$-adenyllyl cyclase coupling underlie the reduced catecholamine responsiveness that is a hallmark of human and animal models of heart failure (2). Studies conducted in a variety of animal models of cardiac hypertrophy (3, 4), heart failure (5, 6), and ischemia (7) and in a model of in vivo desensitization (8) indicate that primary alterations in the $\beta$-adrenergic receptor-$G_{sa}$-adenyllyl cyclase pathway do occur distal to the receptor. In all of these models, there is a global reduction in adenyllyl cyclase activation in cardiac sarcolemma, which can be associated with a reduction in $G_{sa}$ activity, as assessed by the S49 cdc2 reconstitution assay. Changes in the amount of $G_{sa}$ in these reports, however, are relatively small (~40%) considering the abundance of $G_{sa}$ in cardiac membranes. Thus, whether alterations in the expression of $G_{sa}$ in pathophysiological states could contribute in an important way to the altered cAMP production in the failing hearts remains to be elucidated. A recent study in S49 lymphoma cells suggested that the availability of adenyllyl cyclase, rather than the amount of $G_{sa}$ protein, is the limiting factor for agonist stimulation of adenyllyl cyclase (9). The role of stoichiometry in the regulation of $\beta$-adrenergic receptor-$G_{sa}$-adenyllyl cyclase interactions remains unknown in cardiocytes, particularly in the intact functioning heart. Thus, we wished to examine whether alteration in the amount of $G_{sa}$ in the heart affects cAMP production. For these reasons, we overexpressed the short isof orm of $G_{sa}$ in the hearts of mice into which a $G_{sa}$ minigene construct under the control of a rat $\alpha$-myosin heavy chain ($\alpha$-MHC) promoter (10) had been introduced as a transgene. In this study, we assess the efficacy of the promoter construct and the effects of $G_{sa}$ overexpression on adenyllyl cyclase activity in sarcolemmal membranes prepared from the hearts of transgenic mice.

Methods

Construction of the transgene. A 0.9-kb EcoRI–XbaI (blunted) fragment of the rat $\alpha$-MHC gene, containing a 0.6-kb promoter portion, the first exon, the first intron, and the first 43 bp of the second exon proximal to the initiation ATG, was fused to a 1.1-kb Xhol (blunted)–Mflf fragment of the dog $G_{sa}$ cDNA containing exons 1–12, followed by a 1.3-kb Mflf–BanHI fragment of the human $G_{sa}$ gene containing intron 12, exon 13, and the polyadenylation signal (Fig. 1). We used this human gene fragment because we could not obtain the canine equivalent even after repeated library screening. The amino acid sequence within this domain is identical in the human and canine $G_{sa}$, and thus the putative chimeric $G_{sa}$ protein should possess the same amino acid sequence as the wild type. Furthermore, it has been previously reported that the addition of introns increases transcriptional efficiency in
transgenic mice (11). The fusion construct was amplified in a pGEM-7Z plasmid (Promega, Madison, WI). The EcoRI–BamHI 3.3-kb transgene was then purified using a Elutip-D column (Schleicher & Schuell, Keene, NH) and prepared for microinjection, as previously described (12).

Production of transgenic mice. C57BL/6J mice (purchased from Jackson Laboratory, Bar Harbor, ME) were used as embryo donors. Founder transgenic mice were created by microinjection of ~1,000 copies of the transgene into the male pronucleus of the fertilized mouse eggs, as previously described (12). Microinjected eggs were implanted into the oviduct of 1-d pseudopregnant female mice and carried to term. Positive founders were bred to adult normal C57BL/6 X C3H (B6C3F1) F1 hybrid females to establish independent germelines.

Screening of transgenic mice by genomic southern blotting. 3 wk after the birth of animals resulting from the microinjected eggs, total genomic DNA was extracted from the tail as described elsewhere (13). Genomic Southern blots were performed with 10 µg of this DNA cut with BamHI. Hybridization was performed using a 0.5-kb BamHI–BamHI fragment of the Gαs cDNA as probe at 42°C in a 50% formamide solution containing 5x SSC, 5x Denhardt’s solution, 25 mM sodium phosphate (pH 6.5), 0.25 mg/ml salmon sperm DNA, and 0.1% SDS. The probe was radiolabeled with [32P]dCTP, using the Multiprime DNA Labeling System (Amersham Corp., Arlington Heights, IL). The blot was hybridized for 48 h and then washed in a solution containing 0.2% SDS and 0.2x SSC at 60°C for 30 min, followed by autoradiography. Adult mice of both sexes (8–12 wk old) were used in further experiments.

RNA isolation and northern blot analysis. Total RNA was isolated from heart and other tissues. Prehybridization and hybridization were performed at 42°C in the 50% formamide solution previously described, using the same BamHI–BamHI 0.5-kb cDNA fragment as probe. After 24 h of hybridization, the blot was washed in a solution containing 0.2x SSC and 0.2% SDS at 60°C for 30 min, followed by autoradiography. Blots were then erased and rehybridized with a 28S rRNA oligonucleotide probe. The amount of Gαs mRNA expression was standardized using the 28S rRNA content as a control.

Membrane preparation and western blot analysis. One control mouse from the same founder line was sacrificed at the same time as each transgenic mouse. Hearts were dissected from the mice and homogenized in 10 mM Tris-HCl, pH 8.0, using a Polytron (Brinkmann Instruments, Westbury, NY). The homogenate was centrifuged twice at 48,000 g for 10 min and filtered through gauze. The pellet was then resuspended in a 100 mM Tris-HCl pH 7.2, 1 mM EDTA, 5 mM MgCl2 solution and rehomogenized. Protein concentration was measured by the method of Bradford (14) using BSA as the standard. Membranes were then aliquoted to be used for the adenyl cyclase and Gαs reconstitution assays and Western blotting. 20 µg of each membrane preparation was electrophoresed on a 4–20% gradient SDS–polyacrylamide gel. Proteins were transferred to a polyvinylidene fluoride membrane (Immobilon, Millipore, Bedford MA) for Western blot immunodetection.

Detection was performed with a 1:2,000 dilution of anti-Gαs antiserum (New England Nuclear, Boston, MA), followed by a 1:300 dilution of anti-rabbit Ig peroxidase-linked species-specific whole antibody using the ECL detection system (Amersham Corp.). This antibody detected both murine and canine Gαs proteins. After checking the linear relationship between staining and the amount of protein analyzed, Gαs protein was quantitated by densitometry, using a computing densitometer (model 300 Δ, Molecular Dynamics, Sunnyvale, CA).

Reconstitution of Gαs into S49 cyc− membranes (quantification of functional Gαs). Using the stable reconstitution protocol devised by Sternweis and Gilman (15), cardiac membranes were first solubilized in 2% cholate in a buffer of 16 mM Tris, pH 8.0, 0.8 mM EDTA, 0.8 mM DTT. The cholate extract was centrifuged at 20,000 g for 30 min, the endogenous adenyl cyclase was inactivated by incubation at 30°C for 10 min, and the supernatant was diluted into a Lubrol buffer (6) in preparation for reconstitution into 60 µg of S49 cyc− membranes, which were prepared according to the method of Ross et al. (16). AlF3-responsive adenyl cyclase activity was assayed over a range of solubilized cardiac membrane (1.5–4.5 µg for the crude membrane preparation) at 30°C for 15 min; under these conditions, it is known to produce a linear response. The slope of this line (pmoles of cAMP per minute versus added solubilized membrane preparation) was used as a measure of Gαs functional activity (6). Measurements were performed with a control from the same founder line for each transgenic sample.

Na+, K+-ATPase activity. As an index of the consistency of the membrane preparation, Na+, K+-ATPase enzymatic activity was measured according to the method of Jones et al. (17).

Adenyl cyclase assay. 15 µg per tube crude cardiac membrane preparations was used for the adenyl cyclase assay. Adenyl cyclase activity was measured by a modification of the method of Salomon (18). Briefly, the fixed time assays were performed in a final volume of 100 µl of a solution containing 20 mM Hepes, pH 8.0, 5 mM MgCl2, 0.1 mM cAMP, 0.1 mM ATP and [32P]ATP (4 µCi per assay tube), 1 mM creatine phosphate, 8 µg/ml creatine phosphokinase, and 0.5 mM 3-isobutyl-1-methyl-xantine as an inhibitor of cAMP phosphodiesterase. The reaction mixture was incubated at 30°C for 15 min, and the reaction was stopped by the addition of 100 µl of 2% SDS. CAMP was separated from ATP by passing through Dowex (BioRad Laboratories, Richmond, CA) and alumina columns, successively. To monitor recovery throughout the assay, H-labeled CAMP was included in the incubation mixture. The radioactivity was measured by liquid scintillation counting. Stimulated adenyl cyclase activities were measured with addition of 100 µM GTP ±100 µM isoproterenol (GTP+iso), 100 µM guanosine 5’-O-(3-thio)triphosphate (GTPYs), 10 mM NaF, or 100 µM forskolin. All measurements were performed in quadruplicate, with a nontransgenic control from the same founder line for each transgenic sample. cAMP production in the presence of GTP+iso was linear over 20 min in these preparations.
Progress curves with different concentrations of guanyl-5’-O-imidodiphosphate (GppNHp; from 0.017 to 333 μM) were obtained by increasing the final incubation volume to 1.0 ml, withdrawing 100 μl aliquots from these incubations at the indicated times (every 3 min), and stopping the reactions by adding the withdrawn aliquots to 100 μl of 2% SDS (19). Results of the progress curves were standardized by expressing them as a percentage of the maximal production of cAMP achieved at 30 min with 333 μM GppNHp. Steady-state slopes of cardiac adenyl cyclase activity were calculated from 12 to 21 min, over which activity was constantly linear. Initial slopes were estimated by calculation of the regression line forced to pass through the origin between 0 and 9 min. The significance of this regression line was always checked.

β-Adrenergic receptor agonist binding studies. Competitive inhibition agonist binding curves were constructed as previously described (20), using 85 μl of the crude sarcolemma, 25 μl of 125I-cyanopindolol (0.07 nM), 25 μl of isoproterenol (10−5 to 5 × 10−4 M) with 22 concentrations of isoproterenol, and 15 μl of Tris buffer. Assays were performed in duplicate, incubated at 37°C for 40 min, terminated by rapid filtration on GF/C filters, and counted in a gamma counter for 1 min. The binding data were analyzed by the LIGAND program (21).

In the computer analysis, the F test was used to compare the best fit for the ligand binding competition data. The best fit, two-site versus one-site, was determined by the p value for the F test. When the data were best fitted to a single low affinity site, the number of receptors in the high affinity state was set to 0.

Statistical analysis. Comparisons between transgenic and control animal values were made using a paired t test. P < 0.05 was taken as a minimal level of significance.

Results

Production of transgenic mice. We screened 116 mice (57 male and 59 female) resulting from injection of fertilized eggs. Of these mice, 10 (2 male and 8 female mice) were positive, as shown by genomic Southern blotting with a 0.5-kb portion of the Gsa cDNA as probe (Fig. 2). Breeding of these 10 founder animals with normal mice gave five independent germelines. Three of the initial founders remained infertile. Two other founders produced no positive litters, suggesting that these two mice were probably chimeric.

Gsa expression in transgenic mice. By Northern blot analysis of total cardiac RNA from the five independent germelines and from normal mice, we found that three of these lines were overexpressing Gsa mRNA in the heart (Fig. 3). Two Gsa mRNA species of different sizes were detected in transgenic mice. The size of the smaller, more abundant Gsa mRNA species (the “major” band) was as expected if the Gsa transgene RNA were correctly spliced and is the same size as the endogenous Gsa message. We also detected a larger, but much less abundant message (the “minor” band). We do not know the exact nature of this message; however, it could be an incompletely spliced species containing additional gene sequences (see Fig. 1). Thus we quantitated the major Gsa mRNA species as representing the expression of transgenic Gsa mRNA. Two lines (18 and 49) both showed an eightfold overexpression of Gsa mRNA. One line (39) showed a 38-fold overexpression. The two other transgenic lines did not show any overexpression. Line 39, which showed the highest expression of Gsa mRNA, was further analyzed in the following experiments.

To assess the specificity of expression produced with the α-MHC promoter, Northern blot analysis was performed, using total RNA extracted from lung, liver, kidney, muscle, and brain. For this purpose, mice from line 39 were compared with control

\[\text{Figure 4. Gsa mRNA expression in various tissues of transgenic mice. Each lane contains 30 μg of total RNA, which was isolated from different mouse tissues. Samples were electrophoresed in a 1.0% agarose formaldehyde gel. The 32P-labeled probe used for hybridization was either a 0.5-kb BamHI–BamHI portion of the Gsa cDNA (top panel) or an oligonucleotide corresponding to the 28S ribosomal RNA sequence (bottom panel). At the top of the figure are indicated the different tissues tested. T indicates a transgenic animal from line 39; C indicates a nontransgenic control from the same line.}\]
mice from the same line (Fig. 4). We used hybridization with a 
32P-labeled oligonucleotide corresponding to the 28S ribosomal RNA sequence as an internal control for total RNA loading and transfer efficiency. This analysis showed a difference in Gsa mRNA expression only in brain. This difference between transgenic and control animals, however, did not reach a level comparable to that observed in the heart (2-fold overexpression in the brain versus 38-fold in the heart). Similar cardiac-specific expression was also seen in other lines, including line 18 (data not shown).

Western blotting of cardiac Gsa protein was performed on membranes from transgenic mice overexpressing Gsa mRNA, using a commercially available antisera specific for Gsa (Fig. 5). Densitometry, using the long Gsa isoform as an internal control of loading and transfer, gave a semiquantitative assessment of Gsa protein overexpression. Line 39, which showed a 38-fold overexpression of Gsa mRNA, demonstrated a 2.8-fold overexpression of the protein. The degree of Gsa overexpression was consistent among offspring and generations within the same line (Fig. 5 b). In contrast, using an antisera specific for Gα2 (22), we did not find any difference between transgenic and control mice.

**Functional Gs activity.** To assess whether the overexpressed Gsa protein was functional, we measured Gs activity by a reconstitution assay in sarcolemma prepared from transgenic mice, as compared with control mice from the same line (Fig. 6). This assay demonstrated increased functional Gs activity in the hearts of transgenic mice. This activity was higher in line 39 (188±10%, mean±SEM) compared with control animals from the same line. Thus, increased functional activity accompanied the increase in Gsa protein and mRNA levels. However, the absolute increment over control levels was not maintained; there were a 38-fold increase in mRNA (38±3, n = 4), a 2.8-fold increase in protein (2.8±0.2, n = 8), and a 1.9-fold increase in Gsa functional activity (1.9±0.1, n = 4). A similar pattern was observed in line 18: there was an 8-fold increase in mRNA (81±0.7, n = 4), a 1.4-fold increase in protein (1.4±0.2, n = 6), and a 1.2-fold (1.2±0.05, n = 5) increase in Gsa functional activity.

**Effect of Gsa protein overexpression on basal and stimulated steady-state cardiac adenylyl cyclase activity.** To assess whether Gsa protein overexpression in the heart resulted in increased adenylyl cyclase activity, we first compared the steady-state adenylyl cyclase activity between transgenic and control animals by measuring the production of cAMP in sarcolemmal membranes after 15 min of incubation, under basal or stimulated conditions. However, we were unable to identify any significant increase in steady-state adenylyl cyclase activity, under basal or stimulated conditions (GTP + iso, GTPγS, NaF, and forskolin) (Fig. 7).

**Effect of Gsa protein overexpression on the time course of activation of cardiac adenylyl cyclase by Gpp(NH)p.** To assess further whether Gsa protein overexpression in the heart resulted in a more rapid stimulation of adenylyl cyclase, we constructed a progress curve of cAMP production under Gpp(NH)p stimulation following the approach and protocol described by Birnbaum et al. (19). With a concentration of 111 μM Gpp(NH)p in the reaction mixture, the steady-state slopes of cardiac adenylyl cyclase activity were similar between three transgenic and three control mice (Fig. 8 a). The early time points, however, showed a significantly higher production of cAMP in transgenic as compared with control mice at 3, 6, and 9 min (Fig. 8 b). This was reflected as a decrease in the lag period for Gpp(NH)p to exert its effect in stimulating adenylyl cyclase in transgenic mice.
as compared with control mice. Varying the concentration of GppNHp exerted the same effect on the steady-state production of cAMP in transgenic and control mice (Fig. 9a). The initial slopes, however, significantly differed between transgenic and control mice, independently of the concentration of GppNHp that was used (Fig. 9b). The initial slope was significantly lower than the steady-state slope in control animals (Fig. 9c), reflecting the existence of a lag period in the progress curve. In contrast, in transgenic animals, the initial slope was similar to the steady-state slope (Fig. 9d), reflecting a disappearance or decrease in the lag period, independently of the concentration of GppNHp that was used.

**Figure 7.** Basal and stimulated cardiac adenylyl cyclase activity in transgenic mice. The adenylyl cyclase activity in 15 µg of crude cardiac membrane was assayed for 15 min at 30°C, under basal conditions or stimulated by the following agents: GTP + iso, GTPγS, NaF, or forskolin. Control values are represented as open bars; values for transgenic mice (line 39) are represented as solid bars. All measurements were performed in quadruplicate. Results are expressed as the mean±SEM (n = 8, p = NS).

**Figure 8.** Time courses of activation of cardiac adenylyl cyclase by 111 µM GppNHp in transgenic and control mice. Progress curves of adenylyl cyclase activity were constructed according to the protocol described in Methods in three control and three transgenic mice (line 39), in the presence of 111 µM GppNHp. Results were standardized by expressing them as a percentage of the maximal production of cAMP achieved at 30 min with 333 µM GppNHp. a shows the lag period necessary for GppNHp to exert its stimulatory effect in cardiac membranes from control mice (open circles); this lag period is decreased in cardiac membranes from transgenic mice (closed circles). Results are mean±SD of three control and three transgenic animals. b shows individual results between 0 and 9 min, with a statistically significant difference (*) between transgenic and control mice.

**Discussion**

For over 40 yr, data have accumulated to indicate that sympathetic activation of the heart becomes impaired in states of cardiac stress and that this process could contribute to eventual cardiac decompensation and heart failure (2). Decreases in total β-adrenergic receptor density, the high affinity fraction, G, activity, and adenylyl cyclase catalytic content have all been suggested as contributing to the process. We have also identified a loss in G, functional activity accompanied by a decrease in Gαs mRNA content as a relative early occurrence during the development of cardiac hypertrophy associated with chronic pressure overload produced by aortic banding (4). However, the decrement in Gαs content or activity reported in these studies, including ours, was relatively small (~40%). Since Gαs protein...
exists in abundance relative to proteins such as receptors and adenyl cyclase in cardiac membranes, it remains unknown whether a small change in the content of Gsα generates any functionally significant alteration.

To assess these proposals critically, therefore, it is first important to examine the effect of changing the content of any one of these components in the normal heart, free of the confounding factors associated with the syndrome of heart failure. The availability of transgenic methods to alter the content of a particular gene product in the intact animal allows the assessment in the heart itself of altering the ratio of Gsα relative to receptor and the catalyst adenyl cyclase. Because it would be both informative and simpler than attempting to decrease Gsα content, we first chose to enhance Gsα expression in a cardiac-specific manner in transgenic mice, although a decrement in Gsα expression is commonly observed in animal models of heart failure. Three results of these initial studies are important to consider.

**Cardiac-specific expression with the α-MHC promoter.** To induce cardiac-specific overexpression of Gsα, we used a portion of the rat α-MHC gene containing 0.6 kb of the α-MHC promoter (10). In vitro, this portion of the α-MHC gene can direct reporter gene expression specifically in cardiac myocytes. The upstream portion of the mouse α-MHC gene has been previously used to generate transgenic mice (23, 24). In these experiments, a chloramphenicol acetyltransferase gene was used to quantify the ability of different constructs to drive gene expression in transgenic mice. This previous study found that 3.0 kb upstream of the mouse α-MHC gene (corresponding to a

### Table I. Agonist Binding Studies

<table>
<thead>
<tr>
<th></th>
<th>Control (n = 10)</th>
<th>Transgenic (n = 9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoproterenol binding affinity (nM)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K_i</td>
<td>6.3±2.0</td>
<td>20.0±8.8</td>
</tr>
<tr>
<td>K_c</td>
<td>376±158</td>
<td>956±672</td>
</tr>
<tr>
<td>High affinity receptor sites (%)</td>
<td>55±4</td>
<td>73±7*</td>
</tr>
<tr>
<td>Low affinity receptor sites (%)</td>
<td>45±4</td>
<td>27±7*</td>
</tr>
</tbody>
</table>

* P < 0.05.
region where the sequence is preferentially conserved between mouse and rat) is competent to direct expression of the reporter gene in a cardiac-specific way. However, linkage of the chloramphenicol acetyltransferase gene to a short portion of the α-MHC gene with only 138 bp upstream of the transcriptional start site did not direct expression in either muscle or nonmuscle cells (23). The results of our study clearly demonstrate that, using the rat promoter, only 0.6 kb 5' of the transcriptional start site is sufficient to direct cardiac-specific expression of a transgene. The level of expression of \( G_{\alpha} \) mRNA, however, differed among our positive lines of transgenic animals. These differences in the expression level of the transgene may be related to differences in copy number or in the chromosomal position of integration of the foreign DNA (25). In another study in which SV40 large T antigen was overexpressed in the heart using a similar α-MHC promoter, the amount of large T antigen overexpression differed among individuals and different generations even within the same line (26). This contrasts with our results, in which \( G_{\alpha} \) overexpression was consistently maintained across different generations and \( G_{\alpha} \) mRNA content was directly related to \( G_{\alpha} \) protein content across different transgenic lines. These differences may result from the different nature of the transgene products (a viral oncprotein versus a housekeeping gene product) or from the inclusion of intronic sequences in our construct.

Since no overexpression was observed in skeletal muscle, in particular, or in a variety of other tissues (except brain), this analysis underscores the high degree of specificity of the 0.6-kb rat α-MHC promoter for cardiac muscle in our study. In contrast with a previous report in which the mouse α-MHC upstream region was used (24), we did not observe any expression of our transgene in lung.

**Relationship of \( G_{\alpha} \) protein levels to mRNA content.** An obvious discrepancy exists between the steady-state mRNA levels induced by the transgene and the resulting increase in \( G_{\alpha} \) protein content. One of several mechanisms might explain this finding. The size of the major \( G_{\alpha} \) mRNA species detected in the transgenic mice is similar to that of endogenous \( G_{\alpha} \) mRNA, as we expected would be the case if the RNA precursor were correctly spliced. This finding makes it unlikely that incorrect processing of the precursor RNA contributed to the noted discrepancy. We have also detected another minor \( G_{\alpha} \) mRNA species in transgenic mice; the size of this mRNA species is similar to that of the transgene itself (\( G_{\alpha} \) cDNA plus intron 12; see Fig. 3). When the transgene was constructed, we ensured that the Kozak consensus sequence (27) present in the endogenous \( G_{\alpha} \) mRNA would be recapitulated. The total 5' flanking sequence, based on the size of the principal mRNA species detected, is similar to that of the endogenous mRNA. Nevertheless, we cannot exclude the possibility that the chimeric \( G_{\alpha} \) mRNA is less efficiently translated than the wild-type message. It is also possible that the explanation for the discrepancy between mRNA and protein content has a posttranslational basis in which the nascent protein is rapidly catabolized. \( G_{\alpha} \) exists as a heterotrimeric complex in association with \( \beta \gamma \) subunits. Rapid turnover of individual components of a multisubunit protein has previously been shown when only one of the subunits is overexpressed in transfected cell lines (28). It is possible that \( \beta \gamma \) availability is rate limiting and that "free" \( G_{\alpha} \) subunit is rapidly degraded within the cardiocyte. Recently, it has been shown that \( G_{\alpha} \) is palmitoylated, which is likely a requirement for its efficient association with the plasma mem-

brane (29, 30). We cannot readily assess whether incomplete posttranslational processing of \( G_{\alpha} \) in the transgenic cardiocytes might contribute to lower than expected steady-state levels. Since \( G_{\alpha} \) has been found in soluble fractions (31), we compared the amount of \( G_{\alpha} \) in soluble fractions between transgenic and control mice, but found no difference (data not shown).

To confirm that the overexpressed \( G_{\alpha} \) protein was functional, the \( G_i \) activity of sarcolemma preparations from transgenic mice was measured by reconstitution into S49 cyc- membranes and compared with that from control mice from the same line. \( G_{\alpha} \) functional activity was increased by 88% in the hearts of transgenic mice in comparison with control animals. This increase in cardiac \( G_{\alpha} \) functional activity does not account for all the overexpressed \( G_{\alpha} \) protein, since a semiquantitative assessment by densitometry after Western blotting detected a 180% increase in membrane \( G_{\alpha} \) protein. Whether this discrepancy relates to incomplete processing of a portion of the \( G_{\alpha} \) protein (e.g., palmitoylation) has not been determined.

**Effect of increased \( G_{\alpha} \) on cardiac adenylyl cyclase activity and β-adrenergic receptor agonist binding.** To test the hypothesis that overexpression of \( G_{\alpha} \) protein in the heart increases adenylyl cyclase activity, measurements of adenylyl cyclase activity under basal and stimulated conditions were compared between transgenic and control animals from the same line. Our data indicate that, under steady-state conditions, \( G_{\alpha} \) overexpression in the heart does not alter the maximal number of \( G_{\alpha} \) - adenylyl cyclase complexes formed in myocytes. There are a variety of studies suggesting that the concentration of \( G_i \) is severalfold greater than that of both the β-adrenergic receptor and the catalytic adenylyl cyclase in cell membranes (9, 32). However, it is not clear that the availability of the \( G \) protein is functionally limiting in the process of signal transduction in cardiocytes, which are replete in multiple \( G \)-coupled receptors and effectors, including ion channels. Our measurements of adenylyl cyclase activity after catecholamine stimulation suggest that this latter possibility is not operative at least under steady-state conditions.

Next we wished to examine whether an increased level of \( G_{\alpha} \) in the membrane affects the rate of stimulation of adenylyl cyclase activity. Steady-state activities, when plotted as a function of GppNHz concentration, were similar between transgenic and control mice, with an apparent \( K \) value of 0.15 μM in both cases. This \( K \) value is within the 0.05–0.25 μM range previously described in rat liver under the same conditions (19). This lack of difference between transgenic and control mice suggests that under steady-state conditions, the number of GppNHz-bound \( G_{\alpha} \)-adenyl cyclase complexes in the heart is limited by the availability of the adenylyl cyclase, irrespective of the amount of GppNHz-bound \( G_{\alpha} \). However, the progress curves of adenylyl cyclase activation did show a difference at the early time points; we observed an accelerated activation of adenylyl cyclase in transgenic mice as compared with control mice, i.e., cAMP production at 3, 6, and 9 min was significantly higher in transgenic mice. This observation was independent of the concentration of GppNHz that was used for the progress curves and led in the transgenic mice to an apparent disappearance or a decrease of the lag period necessary for GppNHz to exert its stimulating effect on adenylyl cyclase activity. This finding, i.e., enhanced rate of adenylyl cyclase activation, can be understood in the following context. A variety of data have previously shown that the rate of exchange of GDP for GTP at the G protein is rate limiting in the activation of adenylyl cy-
uncoupling the stimulatory activities in compensated 298.

Effects of animals will allow one to adenyl cyclase. Compared with the heart.

receptor-Gs coupling +

in the above figures, maximal adenyl cyclase activation remains unchanged in transgenic mice as compared with controls (Figs. 2 and 9), suggesting that maximal catalytic activity is indeed limited by the availability of the enzyme adenyl cyclase.

The availability of the transgenic lines reported in this study will allow one to examine receptor activation in vivo or in isolated cardiomyocytes, as assessed by the ability of catecholamines to increase heart rate, contractility, and cAMP accumulation. The capacity to measure an increase in heart rate and contractility simultaneously following catecholamine stimulation might allow additional insight as to whether a subtle alteration in the efficiency of signal transduction exists in the hearts of animals overexpressing Gsα.

Acknowledgments

This work was supported by National Institutes of Health grants HL-38070, HL-37404, and HL-45332 and by a grant from the Medical Research Division, American Cyanamid Company-Lederle Laboratories. C. Gaudin was supported by Institut National de la Santé et de la Recherche Médicale, George Lurcy Foundation, and Foundation pour la Recherche Médicale.

References


Beta Receptor Function in Mice Overexpressing Gαs 1683